it does not decide whether any specific plaintiffs injury was caused by a drug
All patients should be screened for disordered eating behaviors before starting GLP-1 agonists (for example, via the SCOFF 26 questionnaire for abbreviated five-question screening, the Eating Disorder Examination Questionnaire 27 for a more comprehensive evaluation, or the Binge Eating Scale 28 , which assesses cognitive, behavioral, and emotional aspects of eating)
I think that, especially in the beginning (right now) as these drugs are gaining notoriety and seeing increased usage, its tough to say but in the short-term, those plus-size clothing stores may actually see an increase in demand
The FDA has approved this one for weight loss (you should see the drug label for weight loss management on the packaging)
Chalisa has no conflicts of interest to report